INFINITY PHARMACEUTICALS, INC. Form 8-K May 07, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 7, 2013

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)


Delaware (State or other jurisdiction

000-31141 (Commission 33-0655706 (IRS Employer

of incorporation) File Number) Identification No.)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

780 Memorial Drive, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (617) 453-1000



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

Item 2.02. Results of Operations and Financial Condition.

On May 7, 2013, we issued a press release announcing our results for the quarter ended March 31, 2013 and will conduct a previously-announced, publicly-available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This information and Exhibit 99.1 hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is included in this report:

Exhibit No. Description

99.1 Press release dated May 7, 2013

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFINITY PHARMACEUTICALS, INC.

Date: May 7, 2013 By: /s/ Lawrence E. Bloch, MD, JD

Lawrence E. Bloch, MD, JD

EVP, Chief Financial Officer and Chief Business Officer